NETRIS Pharma Receives Best Biotech Pitch Award at EIC and Johnson & Johnson Healthcare Investor Day
NETRIS Pharma Recognized as a Leading EIC Accelerator Alumni
November 13th, 2024 – LYON, France and GENEVA, Switzerland – NETRIS Pharma announces the successful award of the Best Biotech Pitch during the Pharma Session at the EIC and Johnson and Johnson Investor Day, powered by Bpifrance – Euroquity. The event, held in Paris on November 13th, 2024, brought together some of the most impactful life science companies supported by the EIC Accelerator as well as a selection of the high profile LifeScience investors.
“This award is a strong recognition of NETRIS Pharma’s innovative approach to overcoming resistance to existing treatments in oncology,” said Christophe Guichard, Chief Financial Officer of NETRIS Pharma. “It highlights our progress thoughout 2024 and momentum, from our successful application to the EIC Accelerator in 2021 and our selection as one of the first 15 life science companies to participate in the EIC Soft Landing Program in San Francisco in May 2024. Building on our promising preliminary clinical outcomes in locally advanced pancreatic cancer patients, we eagerly anticipate 2025, which will bring a wealth of clinical outcomes from our five ongoing clinical studies », he added.
Patrick Mehlen, Chief Executive Officer and Founder of NETRIS Pharma, commented, “The EIC Fund and Bpifrance have been invaluable partners in our journey, and we are excited to further strengthen our collaboration as we continue to advance NP137, our potential first-in-class anti-Netrin-1 antibody to improve treatment outcome for oncology patients”.
